VALET; Philippe

Patent Applications and Registrations

Patent applications and USPTO patent grants for VALET; Philippe.The latest application filed is for "use of shp2 inhibitors for the treatment of insulin resistance".

Company Profile

4.4.8

VALET; Philippe - Toulouse Cedex 4 FR
Valet; Philippe - Toulouse FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Use Of Shp2 Inhibitors For The Treatment Of Insulin Resistance App 20220000869 - YART; Armelle ; et al.	2022-01-06
Methods And Pharmaceutical Compositions For The Treatment Of Post-operative Cognitive Dysfunction App 20210196798 - VALET; Philippe ; et al.	2021-07-01
Method And Pharmaceutical Composition For Use In The Treatment Of Diabetes App 20200171127 - VALET; Philippe ; et al.	2020-06-04
Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer App 20200081009 - Muller; Catherine ; et al.	2020-03-12
Method and pharmaceutical composition for use in the treatment of diabetes Grant 10,426,818 - Valet , et al. October 1, 2	2019-10-01
Inhibition of chemokine CCL7 or receptor CCR3 of same for the treatment and diagnosis of prostate cancer Grant 10,401,365 - Muller , et al. Sep	2019-09-03
Method And Pharmaceutical Composition For Use In The Treatment Of Diabetes App 20180104306 - VALET; Philippe ; et al.	2018-04-19
Inhibition of Chemokine CCL7 or Receptor CCR3 of Same for the Treatment and Diagnosis of Prostate Cancer App 20170131282 - Muller; Catherine ; et al.	2017-05-11
Pharmaceutical composition for use in the treatment of dysfunction associated with aging Grant 9,381,229 - Valet , et al. July 5, 2	2016-07-05
Pharmaceutical Composition For Use In The Treatment Of Dysfunction Associated With Aging App 20150290286 - VALET; Philippe ; et al.	2015-10-15
Use of prebiotics, preferably glucooligosaccharide, for the prevention of the onset of type II diabetes Grant 7,618,951 - Monsan , et al. November 17, 2	2009-11-17
Use of prebiotics, preferably glucooligosaccharide, for the prevention of the onset of type II diabetes App 20060100172 - Monsan; Pierre ; et al.	2006-05-11

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.